BusinessPeregrine Pharmaceuticals Declares Quarterly Dividend on Its Series E Convertible Preferred StockBy Nasdaq OMXMar 7, 2016, 9:05 PM UTC
BusinessPeregrine Pharmaceuticals Announces Formal Commissioning of New, State-of-the-Art Commercial Manufacturing FacilityBy Nasdaq OMXMar 7, 2016, 1:05 PM UTC
BusinessPeregrine to Report Financial Results for Third Quarter of Fiscal Year 2016 Prior to Market Open on March 9, 2016By Nasdaq OMXMar 3, 2016, 9:05 PM UTC
BusinessPeregrine Pharmaceuticals Provides Update on Phase III SUNRISE Trial of BavituximabBy Nasdaq OMXFeb 25, 2016, 9:05 PM UTC
BusinessPeregrine Pharmaceuticals to Present at Two Upcoming Cancer Immunotherapy ConferencesBy Nasdaq OMXJan 20, 2016, 1:05 PM UTC
BusinessPeregrine Pharmaceuticals Provides Update on Planned Expansion of Bavituximab Clinical Program in Lung, Breast and Other CancersBy Nasdaq OMXJan 11, 2016, 1:05 PM UTC
BusinessPeregrine Pharmaceuticals and National Comprehensive Cancer Network (NCCN) Form Clinical Collaboration to Evaluate Novel Cancer Treatment Combinations With BavituximabBy Nasdaq OMXJan 6, 2016, 1:05 PM UTC
BusinessPeregrine Pharmaceuticals Declares Quarterly Dividend on Its Series E Convertible Preferred StockBy Nasdaq OMXDec 7, 2015, 9:05 PM UTC
